Stay updated with breaking news from Aytu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call Transcript February 14, 2024 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.25. Aytu BioPharma, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to the […] ....
Aytu BioPharma (NASDAQ:AYTU – Get Free Report) is scheduled to release its earnings data on Wednesday, February 14th. Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($1.48) earnings per share (EPS) for the quarter. The firm had revenue of $22.10 million for the […] ....
Stonepine Capital Management LLC acquired a new position in Aytu BioPharma, Inc. (NASDAQ:AYTU – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 472,369 shares of the company’s stock, valued at approximately $756,000. Aytu BioPharma accounts for approximately 0.3% of […] ....
Aytu BioPharma (NASDAQ:AYTU – Get Free Report) and Hero Technologies (OTCMKTS:HENC – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations. Valuation & Earnings This table compares Aytu […] ....
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call Transcript September 27, 2023 Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q4 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded. I will now […] ....